logo for BeiGene

BeiGene

Business Services · Massachusetts, United States · 10,000 Employees

View Company Info for Free

About

Headquarters

55 Cambridge Pkwy Ste 700W, Cambridge, Massachu...

Phone Number

(781) 801-1800

Revenue

$3.1 Billion

Stock Symbol

BGNE

Industry

Education General Education

Most Recent Scoops

Dec 11 2024
Project
BeiGene is advancing multiple projects in breast cancer, including a B7H4 targeting ADC nearing the end of dose escalation, a highly selective CDK2 molecule in dose escalation, and plans to start a combination study with a novel BCL2 inhibitor and fulvestrin in 2025.
Dec 11 2024
Project
BeiGene is developing a CDK4 selective inhibitor for breast cancer, with over 100 patients enrolled in the phase 1 study and initial data focusing on monotherapy safety and PK to be presented at San Antonio Breast Cancer Conference.
See all scoops

Highlights

$4.8B

Total Funding Amount

$1B

Most Recent Funding Amount

7

Number of Funding Rounds

View details

Who is BeiGene

Founded in 2010 with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland., China, BeiGene is a global, science-driven biotechnology company, expediting development of a diverse pipeline of novel therapeutics.Explore more
BeiGene's Social MediaPopular SearchesBeigene LtdBeigeneBeiGene IncBeiGene USA IncBeipeng Usa IncSIC Code 87,873NAICS Code 54,541Ticker NASDAQ: BGNEShow more

BeiGene Org Chart

Garrick Yuen

Director, Global Strategic Initiatives, Offic...

PhoneEmail
Yanbin Li

Senior Director, Head of Global Regulatory Pr...

PhoneEmail
Ann Tofolo

Senior Director and Chief of Staff, Business ...

PhoneEmail

PhoneEmail

Is BeiGene your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Compare Similar Companies to BeiGene

Compare insights from companies similar to BeiGene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.

Company Name

Revenue

Number of Employees

Type

Funding

Founded In

Top Executive

BeiGene

$3.1B
10K
Placeholder for Top Executive
$781.5M
2.3K
Placeholder for Top Executive
$353.2M
2K
Placeholder for Top Executive

BeiGene Email Formats

BeiGene uses at least 5 email formats with first.last (ex. John.Smith@beigene.com) being used 89% of the time

BeiGene Email FormatsPercentage

Get Verified Emails

View Email Formats for BeiGene

BeiGene financials insights

Gather financial insights about BeiGene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

BeiGene Employee Growth Rate

Graph showing projected employee growth data for BeiGene

View BeiGene’s full employee growth data

Percentage of growth

1st year Mask

2nd year Mask

BeiGene Tech Stack

A closer look at the technologies used by BeiGene

Most Recent Scoops

Dec 11 2024
Project
BeiGene is advancing multiple projects in breast cancer, including a B7H4 targeting ADC nearing the end of dose escalation, a highly selective CDK2 molecule in dose escalation, and plans to start a combination study with a novel BCL2 inhibitor and fulvestrin in 2025.
Research & Development, Search, Pharmaceuticals
Dec 11 2024
Project
BeiGene is developing a CDK4 selective inhibitor for breast cancer, with over 100 patients enrolled in the phase 1 study and initial data focusing on monotherapy safety and PK to be presented at San Antonio Breast Cancer Conference.
Research & Development, Search, Pharmaceuticals, Clinical Operations, Operations
Dec 11 2024
Project
BeiGene is developing key molecules including a CDK4 selective inhibitor, PNK-RAS inhibitor, and ADCs targeting CEA, B7H3, and B7H4 to build franchises in lung, GI, and breast cancer.
Research & Development, Search, Pharmaceuticals
Dec 11 2024
Project
BeiGene is developing a novel BCL-2 inhibitor with a longer half-life, greater potency against BCL-2, and coverage of specific BCL-2 mutations. The company plans to initiate a study combining this inhibitor with fulvestrant in breast cancer and is exploring its application beyond hematologic malignancies.
Research & Development, Search, Pharmaceuticals
Dec 11 2024
Project
Research & Development, Search, Pharmaceuticals
See more scoops

BeiGene News & Media

Read more news

Top Companies in United States

Top 10 companies in United States by revenue

Top 10 companies in United States by number of employees

Top 10 companies in United States by total funding amount

See top companies

Frequently Asked Questions Regarding BeiGene

Where is BeiGene located?
BeiGene's headquarters are located at 55 Cambridge Pkwy Ste 700W, Cambridge, Massachusetts, 02142, United States
What is BeiGene's phone number?
BeiGene's phone number is (781) 801-1800
What is BeiGene's stock symbol?
BeiGene's stock symbol is BGNE
What is BeiGene's official website?
BeiGene's official website is www.beigene.com
What is BeiGene's Revenue?
BeiGene's revenue is $3.1 Billion
What is BeiGene's SIC code?
BeiGene's SIC: 87,873
What is BeiGene's NAICS code?
BeiGene's NAICS: 54,541
How many employees does BeiGene have?
BeiGene has 10,000 employees
What industry does BeiGene belong to?
BeiGene is in the industry of: Education General, Education
What is BeiGene competition?
BeiGene top competitors include: Regeneron Pharmaceuticals, Jazz Pharmaceuticals, Takeda Oncology, Kite Pharma
What technology does BeiGene use?
Some of the popular technologies that BeiGene uses are: goo.gl, EventPro, Angular 4, DocuSign
Who is the CEO of BeiGene?
BeiGene's CEO is Garrick Yuen
Who is the CFO of BeiGene?
BeiGene's CFO is Zhi Huang
How do I contact BeiGene?
BeiGene contact info: Phone number: (781) 801-1800 Website: www.beigene.com
What does BeiGene do?

Founded in 2010 with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland., China, BeiGene is a global, science-driven biotechnology company, expediting development of a diverse pipeline of novel therapeutics.... Read More

What are BeiGene social media links?
BeiGene Linkedin page BeiGene Twitter page BeiGene Facebook page
How much funding has BeiGene raised to date?
BeiGene has raised $4.8 Billion in 7 funding rounds
When was the last funding round for BeiGene?
BeiGene closed its last funding round on Jul 15, 2020 with the amount of $1 Billion
Who invested in BeiGene?
BeiGene has 10 investors including T. Rowe Price, Hillhouse Capital Group, CITIC Capital Holdings and Hillhouse Capital Group.
Is BeiGene a public company?
Yes, BeiGene is a public company and is traded under the symbol BGNE
See more information about BeiGene

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.